A bill to direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People's Republic of China or other foreign countries, to establish enhanced safeguards for imported drug products, and for other purposes.
About This Bill
Committee
Latest Action · July 21, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The Secure Drug Supply Chain Act of 2026 directs the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs, with particular focus on products from China and other countries engaged in intellectual property theft or forced labor. The bill requires drug manufacturers to report quarterly on the sources of active pharmaceutical ingredients and key starting materials, with emphasis on identifying those sourced from China or other foreign countries of concern, and prohibits registration of foreign drug establishments that use forced labor or violate federal sanctions. The FDA must issue regulations within 180 days of enactment and conduct annual enforcement actions, submitting reports to Congress detailing drugs seized or refused entry and providing legislative recommendations on strengthening pharmaceutical supply chain resilience. The legislation takes effect 180 days after final regulations are issued, affecting pharmaceutical manufacturers, importers, and foreign drug establishments, and aims to reduce American dependence on Chinese-origin pharmaceutical ingredients and materials for national security purposes.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.